Davis TA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135-43. Abstract

Davis TA et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: Results of a Phase II trial of rituximab. J Clin Oncol 1999;17(6):1851-7. Abstract

Gordon LN et al. Phase II trial of individualized rituximab dosing for patients with CD20- positive lymphoproliferative disorders. J Clin Oncol 2005;23(6);[Epub ahead of print]. Abstract

Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol 2004;31(1 Suppl 2):17-21. Abstract

Hainsworth JD et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma – A randomized Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23(6);[Epub ahead of print]. Abstract

Hochster HS et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 2004;22(14 Suppl); Abstract 6502.

Horning S. Something old, something few, something subjective, something déjà vu. J Clin Oncol 2003;21(1):1-2. No abstract available

Huang JE et al. Rituximab plus CHOP followed by maintenance rituximab as initial therapy for aggressive non-Hodgkin’s lymphoma (NHL): Initial results of induction therapy, including rituximab pharmacokinetics, in a Phase II study. Blood 2004;104(11);Abstract 4616.

Leonard JP. The “FLIPI” is no “FLOPI”. Blood 2004;104(5):1233-4. No abstract available

Martin AR et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995;85(12):3671-8. Abstract.

Schouten HC et al. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 2000;11(Suppl 1):91-4. Abstract

Vose JM et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001;19(2):389-97. Abstract